Emerging drugs in endometriosis

Bibliography

• BLUMENKRANTZ MJ, GALLAGHER N, BASHORE RA, TENCKHO H: Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstet. Gynecol. (1981) 57:667-670.
   PubMed Web of Science ®Google Scholar
• HALME J, HAMMOND MG, HULKA JF, RAJ SG, TALBERT LM: Retrograde menstruation in healthy women and in patients with endometriosis. Obstet. Gynecol. (1984) 64:151-154.
   PubMed Web of Science ®Google Scholar
• MIHALYI A, KYAMA CM, SIMSA P, DEBROCK S, MWENDA JM, D’HOOGHE TM: The role of immunological and inflammatory factors in the development of endometriosis: indications for treatment strategies. Therapy (2005) 2(4):623-639.
   Google Scholar
• ZONDERVAN KT, CARDON LR, KENNEDY SH: The genetic basis of endometriosis. Curr. Opin. Obstet. Gynecol. (2001) 13(3):309-314.
   PubMed Web of Science ®Google Scholar
• D’HOOGHE TM, HILL JA: Endometriosis. In: Novak’s Gynecology. Reproductive endocrinology. JS Berek (Ed.), Williams & Wilkins, Baltimore, USA (1996):887-914.
   Google Scholar
• D’HOOGHE TM, BAMBRA CS, RAEYMAEKERS BM, KONINCKX PR: Serial laparoscopies over 30 months show that endometriosis in captive baboons (Papio anubis, Papio cynocephalus) is a progressive disease. Fertil. Steril. (1996) 65(3):645-649.
   PubMed Web of Science ®Google Scholar
• AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE: Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil. Steril. (1997) 67(5):817-821.
   PubMed Web of Science ®Google Scholar
• D’HOOGHE TM, DEBROCK S, HILL JA, MEULEMAN C: Endometriosis and subfertility: is the relationship resolved? Semin. Reprod. Med. (2003) 21(2):243-254.
   PubMed Web of Science ®Google Scholar
• KENNEDY S, BERGQVIST A, CHAPRON C et al.: ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod. (2005) 20(10):2698-2704.
   PubMed Web of Science ®Google Scholar
• ESKENAZI B, WARNER ML: Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am. (1997) 24(2):235-258.
   PubMed Web of Science ®Google Scholar
• FAUCONNIER A, CHAPRON C: Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum. Reprod. Update (2005) 11(6):595-606.
   PubMed Web of Science ®Google Scholar
• HEILIER JF, NACKERS F, VEROUGSTRAETE V, TONGLET R, LISON D, DONNEZ J: Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules. Fertil. Steril. (2005) 84(2):305-312.
   PubMed Web of Science ®Google Scholar
• JONES G, JENKINSON C, KENNEDY S: The impact of endometriosis upon quality of life: a qualitative analysis. J. Psychosom. Obstet. Gynaecol. (2004) 25(2):123-133.
   PubMed Web of Science ®Google Scholar
• ZHAO SZ, WONG JM, DAVIS MB, GERSH GE, JOHNSON KE: The cost of inpatient endometriosis treatment: an analysis based on the Healthcare Cost and Utilization Project Nationwide Inpatient Sample. Am. J. Manag. Care (1998) 4(8):1127-1134.
   PubMed Web of Science ®Google Scholar
• STONES RW, SELFE S: Psychosocial and economic impact of chronic pelvic pain. Balliere’s Clin. Obstet. Gynaecol. (2000) 14(3):415-431.
   PubMed Web of Science ®Google Scholar
• CAMPBELL EM, PETERKIN D, O’GRADY K, SANSON-FISHER R: Premenstrual symptoms in general practice patients. J. Reprod. Med. (1997) 42:637-646.
   PubMed Web of Science ®Google Scholar
• D’HOOGHE TM, DEBROCK S, MEULEMAN C, HILL JA, MWENDA JM: Future directions in endometriosis research Obstet. Gynecol. Clin. North Am. (2003) 30(1):221-244.
   PubMed Web of Science ®Google Scholar
• HUGHES E, FEDORKOW D, COLLINS J, VANDEKERCKHOVE P: Ovulation suppression for endometriosis. Cochrane Database Syst. Rev. (2000) 2:CD000155.
   Google Scholar
• OLIVE DL, PRITTS EA: Treatment of endometriosis. N. Engl. J. Med. (2001) 345(4):266-275.
   PubMed Web of Science ®Google Scholar
• THE PRACTICE COMMITTEE OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE: Endometriosis and infertility. Fertil. Steril. (2004) 81(5):1441-1446.
   PubMed Web of Science ®Google Scholar
• VALLE RF, SCIARRA JJ: Endometriosis: treatment strategies. Ann. NY Acad. Sci. (2003) 997:229-239.
   PubMed Web of Science ®Google Scholar
• GRIESINGER G, FELBERBAUM R, DIEDRICH K: GnRH-antagonists in reproductive medicine. Arch. Gynecol. Obstet. (2005) 273(2):71-78.
   PubMedGoogle Scholar
• FRASER IS, SHEARMAN RP, JANSEN RPS, SUTHERLAND PD: A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust. N. Z. J. Obstet. Gynaecol. (1991) 31:158-163.
   PubMed Web of Science ®Google Scholar
• CIRKEL U, OCHS H, SCHNEIDER HPG: A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. (1995) 59:61-69.
   PubMed Web of Science ®Google Scholar
• CHILD TJ, TAN SL: Endometriosis: aetiology, pathogenesis and treatment. Drugs (2001) 61(12):1735-1750.
   PubMed Web of Science ®Google Scholar
• SAGSVEEN M, FARMER JE, PRENTICE A, BREEZE A: Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst. Rev. (2003) 4:CD001297.
   PubMedGoogle Scholar
• FERNANDEZ H, LUCAS C, HEDON B, MEYER JL, MAYENGA JM, ROUX C: One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum. Reprod. (2004) 19(6):1465-1471.
   PubMed Web of Science ®Google Scholar
• FRANKE HR, VAN DE WEIJER PH, PENNINGS TM, VAN DER MOOREN MJ: Gonadotropin-releasing hormone agonist plus ‘add-back’ hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil. Steril. (2000) 74(3):534-539.
   PubMed Web of Science ®Google Scholar
• TAHARA M, MATSUOKA T, YOKOI T, TASAKA K, KURACHI H, MURATA Y: Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (‘‘draw-back’’ therapy). Fertil. Steril. (2000) 73:799-804.
   PubMed Web of Science ®Google Scholar
• LUCIANO AA, TURKSOY RN, CARLEO J: Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet. Gynecol. (1988) 72(3 Pt 1):323-327.
   PubMed Web of Science ®Google Scholar
• BLEI F, WILSON EL, MIGNATTI P, RIFKIN DB: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol. (1993) 155(3):568-578.
   PubMed Web of Science ®Google Scholar
• PRENTICE A, DEARY AJ, BLAND E: Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst. Rev. (2000) 2:CD002122.
   PubMedGoogle Scholar
• VERCELLINI P, CORTESI I, CROSIGNANI PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil. Steril. (1997) 68(3):393-401.
   PubMed Web of Science ®Google Scholar
• HARRISON RF, BARRY-KINSELLA C: Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil. Steril. (2000) 74:24-30.
   PubMed Web of Science ®Google Scholar
• REDWINE DB: Are the basic assumptions correct-is endometriosis a progressive, self-destructive disease? Fertil. Steril. (2001) 75(1):229-230.
   PubMedGoogle Scholar
• BERGQVIST A, THEORELL T: Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet. Gynecol. Scand. (2001) 80:628-637.
   PubMed Web of Science ®Google Scholar
• SCHLAFF WD, CARSON SA, LUCIANO A, ROSS D, BERGQVIST A: Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil. Steril. (2006) 85(2):314-325.
   PubMed Web of Science ®Google Scholar
• CROSIGNANI PG, LUCIANO A, RAY A, BERGQVIST A: Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum. Reprod. (2006) 21(1):248-256.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM, WEISS MH, SPITZ IM et al.: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. (1991) 74(6):861-866.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM: Role of antiprogestational therapy for meningiomas. Hum. Reprod. (1994) 9(Suppl. 1):202-207.
   PubMed Web of Science ®Google Scholar
• MARTINEAU PA, LEVENTAL M: Large endometrial polyp in a patient on long-term mifepristone therapy. J. Ultrasound Med. (2000) 19:487-489.
   PubMed Web of Science ®Google Scholar
• NEWFIELD RS, SPITZ IM, ISACSON C, NEW MI: Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. (Oxf.) (2001) 54(3):399-404.
   PubMed Web of Science ®Google Scholar
• GROW DR, WILLIAMS RF, HSIU JG, HODGEN GD: Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J. Clin. Endocrinol. Metab. (1996) 81(5):1933-1939.
   PubMed Web of Science ®Google Scholar
• SPITZ IM: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids (2003) 68:981-993.
   PubMed Web of Science ®Google Scholar
• PARFITT K: Martindale. The complete drug reference, 32nd edn. Pharmaceutical Press, London, UK (1999):1447-1448.
   Google Scholar
• BROMHAM DR, BOOKER MW, ROSE GL, WARDLE PG, NEWTON JR: Updating the clinical experience in endometriosis-the European perspective. Br. J. Obstet. Gynaecol. (1995) 102(Suppl.12):12-16.
   PubMedGoogle Scholar
• FEDELE L, BIANCHI S, VIEZZOLI T, ARCAINI L, CANDIANI GB: Gestrinone versus danazol in the treatment of endometriosis. Fertil. Steril. (1989) 51(5):781-785.
   PubMed Web of Science ®Google Scholar
• THE GESTRINONE ITALIAN STUDY GROUP: Gestrinone versus a gonadotropin releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomised, double-blind study. Fertil. Steril. (1996) 66:911-919.
   PubMed Web of Science ®Google Scholar
• MERESMAN GF, AUGÉ L, BARAÑAO RI, LOMBARDI E, TESONE , SUELDO C: Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil. Steril. (2002) 77:1141-1147.
   PubMed Web of Science ®Google Scholar
• MOORE J, KENNEDY S, PRENTICE A: Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst. Rev. (2000) 2:CD001019.
   Google Scholar
• THE ESHRE CAPRI WORKSHOP GROUP: Noncontraceptive health benefits of combined oral contraception. Hum. Reprod. Update (2005) 11(5):513-525.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, FRONTINO G, DE GIORGI O, PIETROPAOLO G, PASIN R, CROSIGNANI PG: Continuous use of an oral contraceptive for endometriosis associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil. Steril. (2003) 80:560-563.
   PubMed Web of Science ®Google Scholar
• RICE VM: Conventional medical therapies for endometriosis. Ann. NY Acad. Sci. (2002) 955:343-352; discussion 389-393, 396-406.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, FEDELE L, PIETROPAOLO G, FRONTINO G, SOMIGLIANA E, CROSIGNANI PG: Progestogens for endometriosis: forward to the past. Hum. Reprod. Update (2003) 9:387-396.
   PubMed Web of Science ®Google Scholar
• ROTONDI M, LABRIOLA D, ROTONDI M: Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur. J. Gynaecol. Oncol. (2002) 23(6):523-526.
   PubMed Web of Science ®Google Scholar
• CHENG MH, YU BK, CHANG SP, WANG PH: A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. J. Chin. Med. Assoc. (2005) 68(7):307-314.
   PubMedGoogle Scholar
• COTTREAU CM, NESS RB, MODUGNO F, ALLEN GO, GOODMAN MT: Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin. Cancer. Res. (2003) 9(14):5142-5144.
   PubMed Web of Science ®Google Scholar
• SMITH WL, GARAVITO RM, DEWITT DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. (1996) 271:33157-33160.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99(21):13926-13931.
   PubMed Web of Science ®Google Scholar
• LANGENBACH R, MORHAM SG, TIANO HF: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 83:483-492.
   PubMed Web of Science ®Google Scholar
• KAUPPILA A, RONNBERG L: Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstet. Gynecol. (1985) 65(3):379-383.
   PubMed Web of Science ®Google Scholar
• ALLEN C, HOPEWELL S, PRENTICE A: Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst. Rev. (2005) 19(4):CD004753.
   Google Scholar
• EFSTATHIOU JA, SAMPSON DA, LEVINE Z et al.: Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil. Steril. (2005) 83(1):171-181.
   PubMed Web of Science ®Google Scholar
• GAETJE R, KOTZIAN S, HERRMANN G, BAUMANN R, STARZINSKI-POWITZ A: Invasiveness of endometriotic cells in vivo. Lancet (1995) 346:1463-1464.
   PubMed Web of Science ®Google Scholar
• GROOTHUIS PG, NAP AW, WINTERHAGER E, GRUMMER R: Vascular development in endometriosis. Angiogenesis (2005) 8(2):147-156.
   PubMedGoogle Scholar
• MATARESE G, DE PLACIDO G, NIKAS Y, ALVIGGI C: Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol. Med. (2003) 9(5):223-228.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, GARG R, BRENNER RM, SCHUBERT G, ELGER W: Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann. NY. Acad. Sci. (2002) 955:373-388.
   PubMed Web of Science ®Google Scholar
• DHINGRA K: Antiestrogen – tamoxifen, SERMs and beyond. Invest. New Drugs (1999) 17(3):285-311.
   PubMed Web of Science ®Google Scholar
• BULUN SE, IMIR G, UTSUNOMIYA H et al.: Aromatase in endometriosis and uterine leiomyomata. J. Steroid. Biochem. Mol. Biol. (2005) 95(1-5):57-62.
   PubMed Web of Science ®Google Scholar
• TAMURA M, DEB S, SEBASTIAN S, KUNIHIRO O, BULUN SE: Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil. Steril. (2004) 81:1351-1356.
   PubMed Web of Science ®Google Scholar
• NOBLE LS, TAKAYMA K, ZEITOUN KM et al.: Prostaglandin E2 stimulates aromatase expression in endometriosis derived stromal cells. J. Clin. Endocrinol. Metab. (1997) 82:600-606.
   PubMed Web of Science ®Google Scholar
• NOBLE LS, SIMPSON ER, JOHNS A, BULUN SE: Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab. (1996) 81:174-179.
   PubMed Web of Science ®Google Scholar
• BULUN SE, SIMPSON ER, WORD RA: Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J. Clin. Endocrinol. Metab. (1994) 78:736-743.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA K, ZEITOUN K, GUNBY RT, SASANO H, CARR BR, BULUN SE: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil. Steril. (1998) 69:709-713.
   PubMed Web of Science ®Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report. J. Clin. Oncol. (2002) 20:3317-3327.
   PubMed Web of Science ®Google Scholar
• GOSS PE, STRASSER K: Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. (2001) 19:881-894.
   PubMed Web of Science ®Google Scholar
• FATEMI HM, AL-TURKI HA, PAPANIKOLAOU EG, KOSMAS L, DE SUTTER P, DEVROEY P: Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod. Biomed. Online (2005) 11(4):455-457.
   PubMed Web of Science ®Google Scholar
• AILAWADI RK, JOBANPUTRAS S, KATARIA M, GURATES B, BULUN SE: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil. Steril. (2004) 81:290-296.
   PubMed Web of Science ®Google Scholar
• BROSENS I: Treatment of endometriosis without aromatase inhibitors. Fertil. Steril. (2004) 82(1):255-256.
   PubMedGoogle Scholar
• EVERS JLH: The second look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression. Fertil. Steril. (1987) 52:502-503.
   Google Scholar
• AMSTERDAM LL, GENTRY W, JOBANPUTRA S, WOLF M, RUBIN SD, BULUN SE: Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil. Steril. (2005) 84(2):300-304.
   PubMed Web of Science ®Google Scholar
• HORVATH JE, TOLLER GL, SCHALLY AV, BAJO AM, GROOT K: Effect of long-term treatment with low doses of the LHRH antagonist cetrorelixon pituitary receptors for LHRH and gonadal axis in male and female rats. Proc. Natl. Acad. Sci. USA (2004) 101(14):4996-5001.
   PubMed Web of Science ®Google Scholar
• SCHULTZE-MOSGAU A, GRIESINGER G, ALTGASSEN C, VON OTTE S, HORNUNG D, DIEDRICH K: New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert. Opin. Investig. Drugs (2005) 14(9):1085-1097.
   PubMed Web of Science ®Google Scholar
• REISSMANN T, FELBERBAUM R, DIEDRICH K, ENGEL J, COMARU-SCHALLY AM, SCHALLY AV: Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum. Reprod. (1995) 10:1974-1981.
   PubMed Web of Science ®Google Scholar
• BARBIERI RL: Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J. Reprod. Med. (1998) 43:287-292.
   PubMed Web of Science ®Google Scholar
• KIILHOLMA P, TUIMALA R, KIVINEN S, KORHONEN M, HAGMAN E: Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil. Steril. (1995) 64:903-908.
   PubMed Web of Science ®Google Scholar
• HORNSTEIN MD, SURREY ES, WEISBERG GW, CASINO LA; for THE LUPRON ADD-BACK STUDY GROUP: Leuprolide acetate depot and hormonal addback in endometriosis: a 12-month study. Obstet. Gynecol. (1998) 91:16-24.
   PubMed Web of Science ®Google Scholar
• HORNSTEIN MD, YUZPE AA, BURRY KA, HEINRICH LR, BUTTRAM VL Jr, ORWOLL ES: Prospective randomised double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil. Steril. (1995) 63:955-962.
   PubMed Web of Science ®Google Scholar
• KUPKER W, FELBERBAUM RE, KRAPP M, SCHILL T, MALIK E, DIEDRICH K: Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online (2002) 5:12-16.
   PubMedGoogle Scholar
• OKADA H, NAKAJIMA T, YOSHIMURA T, YASUDA K, KANZAKI H: The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol. Hum. Reprod. (2001) 7(4):341-347.
   PubMed Web of Science ®Google Scholar
• SCHINDLER AE, CHRISTENSEN B, HENKEL A, OETTEL M, MOORE C: High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol. Endocrinol. (2006) 22(1):9-17.
   PubMed Web of Science ®Google Scholar
• COSSON M, QUERLEU D, DONNEZ J et al.: Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. (2002) 77(4):684-692.
   PubMed Web of Science ®Google Scholar
• WINNEKER RC, FENSOME A, WROBEL JE, ZHANG Z, ZHANG P: Nonsteroidal progesterone receptor modulators: structure activity relationships. Semin. Reprod. Med. (2005) 23(1):46-57.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, OLLAND AM, ZHU Y et al.: Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J. Biol. Chem. (2005) 280(31):28468-28475.
   PubMed Web of Science ®Google Scholar
• BRUNER-TRAN KL, ZHANG Z, EISENBERG E, WINNEKER RC, OSTEEN KG: Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J. Clin. Endocrinol. Metab. (2006) 91(4):1554-1560.
   PubMed Web of Science ®Google Scholar
• IGARASHI TM, BRUNER-TRAN KL, YEAMAN GR et al.: Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil. Steril. (2005) 84:67-74.
   PubMed Web of Science ®Google Scholar
• SHERMAN MR, CORVOL PL, O’MALLEY BW: Progesterone binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. J. Biol. Chem. (1970) 245:6085-6096.
   PubMed Web of Science ®Google Scholar
• LOOSFELT H, ATGER M, MISRAHI M et al.: Cloning and sequence analysis of rabbit progesterone-receptor complementary DNA. Proc. Natl. Acad. Sci. USA (1986) 83:9045-9049.
   PubMed Web of Science ®Google Scholar
• MISRAHI M, ATGER M, D’AURIOL L et al.: Complete aminoacid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem. Biophys. Res. Commun. (1987) 143:740-748.
   PubMed Web of Science ®Google Scholar
• MISRAHI M, LOOSFELT H, ATGER M et al.: Organisation of the entire rabbit progesterone receptor mRNA and of the promoter and 50 flanking region of the gene. Nucleic Acids Res. (1988) 16:5459-5472.
   PubMed Web of Science ®Google Scholar
• ELGER W, BARTLEY J, SCHNEIDER B, KAUFMANN G, SCHUBERT G, CHWALISZ K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to pragonistic and antagonistic activity. Steroids (2000) 65:713-723.
   PubMed Web of Science ®Google Scholar
• SPITZ IM, CHWALISZ K: Progesterone receptor modulators and progesterone antagonists in women’s health. Steroids (2000) 65(10-11):807-815.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, STOCKEMANN K, FRITZEMEIER KH, FUHRMANN U: Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update (1998) 4(5):570-583.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, BRENNER RM, FUHRMANN UU, HESS-STUMPP H, ELGER W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids (2000) 65(10-11):741-751.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, ELGER W, STICKLER T, MATTIA-GOLDBERG C, LARSEN L: The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum. Reprod. (2005) 20(4):1090-1099.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, PEREZ MC, DEMANNO D, WINKEL C, SCHUBERT G, ELGER W: Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr. Rev. (2005) 26(3):423-438. Erratum in: Endocr. Rev. (2005) 26(5):703.
   PubMed Web of Science ®Google Scholar
• JACKSON TA, RICHER JK, BAIN DL, TAKIMOTO GS, TUNG L, HORWITZ KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domainbinding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. (1997) 11:693-705.
   PubMed Web of Science ®Google Scholar
• SWISHER DK, TAGUE RM, SEYLER DE: Effects of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug. Devel. Res. (1995) 36:43-45.
   Web of Science ®Google Scholar
• YAO Z, SHEN X, CAPODANNO I et al.: Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J. Invest. Surg. (2005) 18(4):177-183.
   PubMed Web of Science ®Google Scholar
• BUELKE-SAM J, BRYANT HU, FRANCIS PC: The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod. Toxicol. (1998) 12(3):217-221.
   PubMed Web of Science ®Google Scholar
• COUSE JF, KORACH KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. (1999) 20(3):358-417. Erratum in: Endocr. Rev. (1999) 20(4):459.
   PubMed Web of Science ®Google Scholar
• HARRIS HA, BRUNER-TRAN KL, ZHANG X, OSTEEN KG, LYTTLE CR: A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum. Reprod. (2005) 20(4):936-941.
   PubMed Web of Science ®Google Scholar
• LECCE G, MEDURI G, ANCELIN M, BERGERON C, PERROT-APPLANAT M: Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J. Clin. Endocrinol. Metab. (2001) 86:1379-1386.
   PubMed Web of Science ®Google Scholar
• MALAMAS MS, MANAS ES, MCDEVITT RE et al.: Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J. Med. Chem. (2004) 47:5021-5040.
   PubMed Web of Science ®Google Scholar
• HILLISCH A, PETERS O, KOSEMUND D et al.: Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol. Endocrinol. (2004) 18:1599-1609.
   PubMed Web of Science ®Google Scholar
• HARRIS HA: Estrogen receptor-β: recent lessons from in vivo studies. Mol. Endocrinol. (2006) (In Press).
   Google Scholar
• TAYLOR AH, AL-AZZAWI F: Immunolocalisation of oestrogen receptor β in human tissues. J. Mol. Endocrinol. (2000) 24(1):145-155.
   PubMed Web of Science ®Google Scholar
• DONNEZ J, SMOES P, GILLEROT S, CASANAS-ROUX F, NISOLLE M: Vascular endothelial growth factor (VEGF) in endometriosis. Hum. Reprod. (1998) 13:1686-1690.
   PubMed Web of Science ®Google Scholar
• NAP AW, DUNSELMAN GA, GRIFFIOEN AW, MAYO KH, EVERS JL, GROOTHUIS PG: Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil. Steril. (2005) 83(3):793-795.
   PubMed Web of Science ®Google Scholar
• HULL ML, CHARNOCK-JONES DS, CHAN CL et al.: Antiangiogenic agents are effective inhibitors of endometriosis. J. Clin. Endocrinol. Metab. (2003) 88(6):2889-2899.
   PubMed Web of Science ®Google Scholar
• CHARNOCK-JONES DS, SHARKEY AM, RAJPUT-WILLIAMS J et al.: Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol. Reprod. (1993) 48:1120-1128.
   PubMed Web of Science ®Google Scholar
• NAP AW, GRIFFIOEN AW, DUNSELMAN GA et al.: Antiangiogenesis therapy for endometriosis. J. Clin. Endocrinol. Metab. (2004) 89(3):1089-1095.
   PubMed Web of Science ®Google Scholar
• BECKER CM, SAMPSON DA, RUPNICK MA et al.: Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil. Steril. (2005) 84(Suppl.2):1144-1155.
   PubMed Web of Science ®Google Scholar
• LASCHKE MW, ELITZSCH A, VOLLMAR B, VAJKOCZY P, MENGER MD: Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum. Reprod. (2006) 21(1):262-268.
   PubMed Web of Science ®Google Scholar
• FRASER HM, LUNN SF: Angiogenesis and its control in the female reproductive system. Br. Med. Bull. (2000) 56:787-797.
   PubMed Web of Science ®Google Scholar
• KLAUBER N, ROHAN RM, FLYNN E, D’AMATO RJ: Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat. Med. (1997) 3:443-446.
   PubMed Web of Science ®Google Scholar
• CHISHIMA F, HAYAKAWA S, SUGITA K et al.: Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am. J. Reprod. Immunol. (2002) 48(1):50-56.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK K, OGUNKOLADE W, ELKAK A et al.: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr. Med. Res. Opin. (2002) 18(4):237-241.
   PubMed Web of Science ®Google Scholar
• BULUN SE, ZEITOUN KM, TAKAYAMA K, SASANO H: Molecular basis for treating endometriosis with aromatase inhibitors. Hum. Reprod. Update (2000) 6(5):413-418.
   PubMed Web of Science ®Google Scholar
• HULL ML, PRENTICE A, WANG DY et al.: Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum. Reprod. (2005) 20(2):350-358.
   PubMed Web of Science ®Google Scholar
• EFSTATHIOU JA, SAMPSON DA, LEVINE Z et al.: Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil. Steril. (2005) 83(1):171-181.
   PubMed Web of Science ®Google Scholar
• DOGAN E, SAYGILI U, POSACI C et al.: Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil. Steril. (2004) 82(Suppl. 3):1115-1120.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI S, CANIS M, DARCHA C, DALLEL R, OKAMURA K, MAGE G.: Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil. Steril. (2004) 82(6):1609-1615.
   PubMed Web of Science ®Google Scholar
• COBELLIS L, RAZZI S, DE SIMONE S et al.: The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. (2004) 116(1):100-102.
   PubMed Web of Science ®Google Scholar
• BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352(11):1092-1102.
   PubMed Web of Science ®Google Scholar
• BULLIMORE DW: Endometriosis is sustained by tumour necrosis factor-α. Med. Hypotheses (2003) 60(1):84-88.
   PubMed Web of Science ®Google Scholar
• BEDAIWY MA, FALCONE T, SHARMA RK et al.: Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum. Reprod. (2002) 17(2):426-431.
   PubMed Web of Science ®Google Scholar
• ZHANG RJ, WILD RA, OJAGO JM: Effect of tumor necrosis factor-α on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system. Fertil. Steril. (1993) 59(6):1196-1201.
   PubMed Web of Science ®Google Scholar
• DEBROCK S, DE STROOPER B, VANDER PERRE S, HILL JA, D’HOOGHE TM: Tumour necrosis factor-α, interleukin-6 and interleukin-8 do not promote adhesion of human endometrial epithelial cells to mesothelial cells in a quantitative in vitro model. Hum. Reprod. (2006) 21(3):605-609.
   PubMed Web of Science ®Google Scholar
• SELAM B, KAYISLI UA, GARCIA-VELASCO JA, AKBAS GE, ARICI A: Regulation of fas ligand expression by IL-8 in human endometrium. J. Clin. Endocrinol. Metab. (2002) 87(8):3921-3927.
   PubMed Web of Science ®Google Scholar
• SILLEM M, PRIFTI S, MONGA B, ARSLIC T, RUNNEBAUM B: Integrin-mediated adhesion of uterine endometrial cells from endometriosis patients to extracellular matrix proteins is enhanced by tumor necrosis factor α (TNF α) and interleukin-1 (IL-1). Eur. J. Obstet. Gynecol. Reprod. Biol. (1999) 87(2):123-127.
   PubMed Web of Science ®Google Scholar
• HILL JA, HAIMOVICI F, ANDERSON DJ: Products of activated lymphocytes and macrophages inhibit mouse embryo development in vitro. J. Immunol. (1987) 139:2250-2254.
   PubMed Web of Science ®Google Scholar
• D’ANTONIO M, MARTELLI F, PEANO S, PAPOIAN R, BORRELLI F: Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J. Reprod. Immunol. (2000) 48(2):81-98.
   PubMed Web of Science ®Google Scholar
• D’HOOGHE TM, NUGENT NP, CUNEO S et al.: Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol. Reprod. (2006) 74(1):131-136.
   PubMed Web of Science ®Google Scholar
• FALCONER H, MWENDA JM, CHAI DC et al.: Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum. Reprod. (2006) 21(7):1856-1862.
   PubMed Web of Science ®Google Scholar
• BARRIER BF, BATES GW, LELAND MM, LEACH DA, ROBINSON RD, PROPST AM: Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil. Steril. (2004) 81(Suppl. 18):775-779.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, STAELS B, AUWERX J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. J. Biochim. Biophys. Acta (1996) 1302(2):93-109.
   PubMed Web of Science ®Google Scholar
• CUNARD R, RICOTE M, DICAMPLI D et al.: Regulation of cytokine expression by ligands of peroxisome proliferators activated receptors. J. Immunol. (2002) 168(6):2795-2802.
   PubMed Web of Science ®Google Scholar
• RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 391(6662):79-82.
   PubMed Web of Science ®Google Scholar
• ISSEMANN I PRINCE RA, TUGWOOD JD, GREEN S: The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. (1993) 11:37.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, CHEN J, EVANS RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator activated receptors α and δ. Proc. Natl. Acad. Sci. USA (1997) 94:4312.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. (1995) 270:12953.
   PubMed Web of Science ®Google Scholar
• CUNARD R, RICOTE M, DICAMPLI D et al.: Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. (2002) 168(6):2795-2802.
   PubMed Web of Science ®Google Scholar
• DEVCHAND PR, KELLER H, PETERS JM, VAZQUEZ M, GONZALEZ FJ, WAHLI W: The PPARα-leukotriene B4 pathway to inflammation control. Nature (1996) 384:39.
   PubMed Web of Science ®Google Scholar
• JIANG C, TING AT, SEED B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 391(6662):82-86.
   PubMedGoogle Scholar
• MEIER C, CHICHEPORTICHE R, JUGE-AUBRY C, DREYER M, DAYER J: Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor γ. Cytokines (2002) 18(6):320-328.
   Google Scholar
• YEE LD, SABOURIN CL, LIU L et al.: Peroxisome proliferator-activated receptor γ activation in human breast cancer. Int. J. Oncol. (1999) 15(5):967-973.
   PubMed Web of Science ®Google Scholar
• HOUSTON KD, COPLAND JA, BROADDUS RR, GOTTARDIS MM, FISCHER SM, WALKER CL: Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor γ ligands in uterine leiomyoma. Cancer Res. (2003) 63(6):1221-1227.
   PubMed Web of Science ®Google Scholar
• HEANEY AP, FERNANDO M, MELMED S: PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. (2003) 111(9):1381-1388.
   PubMed Web of Science ®Google Scholar
• PANIGRAHY D, SINGER S, SHEN LQ et al.: PPAR-γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. (2002) 110(7):923-932.
   PubMed Web of Science ®Google Scholar
• PRITTS EA, ZHAO D, RICKE E, WAITE L, TAYLOR RN: PPAR-γ decreases endometrial stromal cell transcription and translation of RANTES in vitro. J. Clin. Endocrinol. Metab. (2002) 87(4):1841-1844.
   PubMed Web of Science ®Google Scholar
• WANICHKUL T, HAN S, HUANG RP, SIDELL N: Cytokine regulation by peroxisome proliferator-activated receptor γ in human endometrial cells. Fertil. Steril. (2003) 79(Suppl. 1):763-769.
   PubMed Web of Science ®Google Scholar
• PRITTS EA, ZHAO D, SOHN SH, CHAO VA, WAITE LL, TAYLOR RN: Peroxisome proliferator-activated receptor-γ ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil. Steril. (2003) 80(2):415-420.
   PubMed Web of Science ®Google Scholar
• HORNUNG D, CHAO VA, VIGNE JL, WALLWIENER D, TAYLOR RN: Thiazolidinedione inhibition of peritoneal inflammation. Gynecol. Obstet. Invest. (2003) 55(1):20-24.
   PubMed Web of Science ®Google Scholar
• LEBOVIC DI, KIR M, CASEY CL: Peroxisome proliferator-activated receptor-γ induces regression of endometrial explants in a rat model of endometriosis. Fertil. Steril. (2004) 82(Suppl. 3):1008-1013.
   PubMed Web of Science ®Google Scholar
• DEMIRTURK F, AYTAN H, CALISKAN AC, AYTAN P, KOSEOGLU DR: Effect of peroxisome proliferator-activated receptor-γ agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J. Soc. Gynecol. Investig. (2006) 13(1):58-62.
   PubMedGoogle Scholar
• SMITH KA: Interleukin-2: inception, impact, and implications. Science (1988) 240:1169.
   PubMed Web of Science ®Google Scholar
• NELSON BH: IL-2, regulatory T cells, and tolerance. J. Immunol. (2004) 172(7):3983-3988.
   PubMed Web of Science ®Google Scholar
• MALEK TR: The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. (2003) 74(6):961-965.
   PubMed Web of Science ®Google Scholar
• GARZETTI GG, CIAVATTINI A, PROVINCIALI M, MUZZIOLI M, DI STEFANO G, FABRIS N: Natural killer activity in stage III and IV endometriosis: impaired cytotoxicity and retained lymphokine responsiveness of natural killer cells. Gynecol. Endocrinol. (1995) 9:125-130.
   PubMed Web of Science ®Google Scholar
• BRAUN DP, GEBEL H, ROTMAN C, RANA N, DMOWSKI WP: The development of cytotoxicity in peritoneal macrophages from women with endometriosis. Fertil. Steril. (1992) 57:1203-1210.
   PubMed Web of Science ®Google Scholar
• MELIOLI G, SEMINO C, SEMINO A, VENTURINI PL, RAGNI N: Recombinant interleukin-2 corrects in vitro the immunological defect of endometriosis. Am. J. Reprod. Immunol. (1993) 30:218-227.
   PubMed Web of Science ®Google Scholar
• ACIEN P, PEREZ-ALBERT G, QUEREDA FJ, SANCHEZ-FERRER M, GARCIA-ALMELA A, VELASCO I: Treatment of endometriosis with transvaginal ultrasound-guided drainage under GnRH analogues and recombinant interleukin-2 left in the cysts. Gynecol. Obstet. Invest. (2005) 60(4):224-231.
   PubMed Web of Science ®Google Scholar
• ACIEN P, QUEREDA FJ, GOMEZ-TORRES MJ, BERMEJO R, GUTIERREZ M: GnRH analogues, transvaginal ultrasound-guided drainage and intracystic injection of recombinant interleukin-2 in the treatment of endometriosis. Gynecol. Obstet. Invest. (2003) 55(2):96-104.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI S, CANIS M, VAURS-BARRIERE C, BOESPFLUG-TANGUY O, DASTUGUE B, MAGE G: DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil. Steril. (2005) 84(Suppl. 2):1180-1190.
   PubMed Web of Science ®Google Scholar
• EYSTER KM, BOLES AL, BRANNIAN JD, HANSEN KA: DNA microarray analysis of gene expression markers of endometriosis. Fertil. Steril. (2002) 77(1):38-42.
   PubMed Web of Science ®Google Scholar
• POLINESS AE, HEALEY MG, BRENNECKE SP, MOSES EK: Proteomic approaches in endometriosis research. Proteomics (2004) 4(7):1897-1902.
   PubMed Web of Science ®Google Scholar
• KYAMA CM, T’JAMPENS D, MIHALYI A et al.: ProteinChip technology is a useful method in the pathogenesis and diagnosis of endometriosis: a preliminary study. Fertil. Steril. (2006) 86(1):203-209.
   PubMed Web of Science ®Google Scholar
• INGELMO JM, QUEREDA F, ACIEN P: Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-α2b in a murine model. Fertil. Steril. (1999) 71(5):907-911.
   PubMed Web of Science ®Google Scholar
• ACIEN P, QUEREDA F, CAMPOS A, GOMEZ-TORRES MJ, VELASCO I, GUTIERREZ M: Use of intraperitoneal interferon α2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil. Steril. (2002) 78(4):705-711.
   PubMed Web of Science ®Google Scholar